Boehringer Ingelheim appoints General Manager and Head of Human Pharma in Saudi Arabia

Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, announced today that it has appointed Waleed Mashak as the company’s General Manager and Head of Human Pharma in Saudi Arabia. He will continue driving the company’s business strategy and wider operations across the Kingdom.

Mashak enjoys more than two decades of industry knowledge and extensive experience in the Middle East pharmaceutical sector, and is regarded as one of the experts in the field. 

He joined Boehringer Ingelheim in 1997, and has since then, assumed various senior roles across a number of business functions. Prior to managing the company’s business in Saudi Arabia, Mashak was Boehringer Ingelheim’s Regional Head of Marketing for prescription medicine across the Near East Middle East and Africa (NEMEA) region.

Enrique Manzoni, Boehringer Ingelheim’s Regional Managing Director, Middle East, Turkey and Africa (META) said, “Saudi Arabia is at the heart of our regional operations in the region and Boehringer Ingelheim is committed to expand its activities in the Kingdom to meet local healthcare demands.” 

“The appointment of Waleed Mashak is a natural extension of our efforts to further drive our operations in the Kingdom. With the current infrastructure changes to the local economy, the potential for the Saudi market is gaining more momentum to create more synergies locally and around the region, as we continue to support Vision 2030’s health agenda,” added Manzoni. 

Furthermore, Waleed Mashak, Boehringer Ingelheim’s General Manager and Head of Human Pharma in Saudi Arabia,also noted, “This is an exciting time for Boehringer Ingelheim in Saudi Arabia. Boehringer Ingelheim has afocused strategy on different disease areas such as cardiovascular, respiratory diseases, and diabetes, allowing the company to apply best practices to in the healthcare sector, offering innovative medical solutions, while also drive patient disease awareness programs across the Kingdom.”

“We continue to leverage our partnerships and cooperation with the Ministry of Health to align our activities with that of the Kingdom’s health strategy by working collectively with our partners locally to reach more patients and save more lives,” added Mashak.

In 2014, Boehringer Ingelheim initiated critical steps in manufacturing 26 products to Saudi Arabia. The aim is to develop third party secondary production with key local partners such as Tabouk and Cigalah in an effort to drive the shared commitment with the government in providing a reliable supply of essential medicines for patients. 

 In Saudi Arabia, Boehringer Ingelheim continues to play a critical role in raising public awareness around key chronic disease areas including stroke by focusing on symptoms, the development of specialized stroke units across hospitals, in addition to the urgency of catering to patients within the ‘golden hour’ to be able to save lives in an efficient and timely manner.